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Abstract
Background: Frequency relapses are common in Philadelphia chromosome-positive (Ph-positive) acute
lymphoblastic leukemia (ALL) following tyrosine kinase inhibitors (TKIs). CDKN2A/B is believed to contribute to this
chemotherapy resistance.
Methods: To further investigate the association between CDKN2 status and TKI resistance, the prevalence of CDKN2
deletions and its correlation with a variety of clinical features was assessed in 135 Ph-positive ALL patients using
interphase fluorescence in situ hybridization (I-FISH).
Results: Results showed that no difference occurred between patients with CDKN2 deletion (44/135) and wild-type
patients in sex, age, and complete remission (CR) rate following induction chemotherapy combined with tyrosine
kinase inhibitors (TKIs). However, CDKN2 deletion carriers demonstrated higher white blood cell (WBC) count,
enhanced rates of hepatosplenomegaly (P = 0.006), and upregulation of CD20 expression (P = 0.001). Moreover,
deletions of CDKN2 resulted in lower rates of complete molecular response (undetectable BCR/ABL), increased
cumulative incidence of relapse, short overall survival (OS), and disease-free survival (DFS) time (P < 0.05) even
though these patients received chemotherapy plus TKIs followed by allogenic hematopoietic stem cell
transplantation (Allo-HSCT). In the case of 44 patients who presented with CDKN2 deletion, 18 patients were
treated with dasatinib treatment, and another 26 patients were treated with imatinib therapy, and our study found
that there were no differences associated with OS (P = 0.508) and DFS (P = 0.555) between the two groups.
Conclusions: CDKN2 deletion is frequently acquired during Ph-positive ALL progression and serves as a poor
prognostic marker of long-term outcome in Ph-positive ALL patients with CDKN2 deletion even after the
second-generation tyrosine kinase inhibitor treatment.
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Background
Tyrosine kinase inhibitors (TKIs) were currently used
as front line chemotherapy agents in Philadelphia
chromosome-positive acute lymphoblastic leukemia
(Ph-positive ALL) patients. Although favorable clinical
outcome and complete remission (CR) has been reported,
TKI resistance demonstrates a higher relapse rate and
short survival time. Development of resistance is a con-
tinuous clinical challenge [1]. Therefore, exploration of
TKI resistance mechanism and its associated new prog-
nostic markers becomes a model of therapy for particular
subgroups of patients who have showed no significant
benefit from TKI therapeutic trials [2].
CDKN2A/B deletions including tumor suppressor genes
INK4A, INK4B, and/or ARF commonly occur in all types
of lymphoid malignancies and account for approximately
55 % of adult T-ALL and 30 % of BCP-ALL [3]. Our previ-
ous research reported the unfavorable prognostic role of
CDKN2 gene deletion in long-term leukemia outcomes
[4]. Especially, an association study between CDKN2 dele-
tion and clinical outcomes suggested CDKN2 as a poor
prognostic marker, and this has been observed in 29 % of
BCR-ABL-positive ALL [5]. Previous studies failed to dem-
onstrate this phenomenon as they were limited by a small
sample size and were unable to investigate the correlation
between CDKN2 deletion and immunophenotypic or
molecular characteristics. Our current study enrolled 135
newly diagnosed patients who were Ph-positive ALL pa-
tients in multi-cancer centers, and the prognostic value of
the deletion of CDKN2 gene was assessed.
Methods
Patient information
From January 2008 to December 2014, 135 de novo pa-
tients diagnosed with Ph-positive ALL at the Nanfang
Hospital of Southern Medical University, Guangzhou
Air Force Headquarters Hospital, the Second People’s
Hospital of Guangdong province, and the Hospital of
Guizhou Province following standard bone marrow
morphologic, cytochemical, immunophenotypic criteria
and cytogenetics were included in our study. All pa-
tients received the systematic treatment. Furthermore,
we assessed factors that may affect the prognosis of
the patients such as age, peripheral white blood cell
count of primary diagnosis, hepatosplenomegaly, cyto-
genetics, phenotype, and other clinical data.
Ethics statement
The study protocol was approved by the Ethics Committee
of the Nanfang Hospital of Southern Medical University.
Immunophenotyping by flow cytometry
Immunophenotyping by flow cytometry allowed for the
differentiation of 127 B-ALL patients. All of them were
analyzed and reported according to the European Group
for the Immunological Characterization of Leukemias
(EGIL) criteria [6].
FISH and probes
We included CDKN2A (encoding p16 and p14) and
CDKN2B (encoding p15), the two subunits of CDKN2,
in our current study. The deletion of CDKN2 was de-
fined as the loss of CDKN2A or CDKN2B which con-
tained both hemizygous deletion and homozygous
deletion genotypes. Interphase fluorescence in situ
hybridization (I-FISH) experiments were performed with
commercial kits (Cat No. LH009, Cytocell, Cambridge,
UK) including two red-labeled CDKN2 probe kits, one
red-labeled BCR and one green-labeled and ABL probe
kit according to the manufacturers’ protocols (Fig. 1).
Bone marrow cells of all patients were collected for de-
tection of CDKN2 (covers a 193-kD region of 9q21.3,
extending from 105 kD telomeric of p16 gene to 46 kD
centromeric of CDKN2B) and BCR/ABL. We analyzed
interphase cells according to the manufacturer’s instruc-
tions and the ISCN (2005) criteria [7].
Real-time quantitative polymerase chain reaction
The BCR-ABL expression levels of BCR-ABL were de-
tected by real-time quantitative polymerase chain reaction
(RT-PCR) (Qiagen, Hilden, Germany). ABL was chosen as
an internal control. The results were presented with a
percentage of BCR-ABL/ABL. It was used to evaluate
the complete remission rate of patients following a period
of treatment.
Treatment protocol
According to the National Comprehensive Cancer
Network (NCCN) Guideline Version 1.2014 Acute
Lymphoblastic Leukemia [8], a 4-week induction therapy
(vincristine, daunorubicin or idarubicin, L-asparagines,
and prednisone) was given to all patients with a supple-
mentary dose of imatinib 400 mg qd per day or dasatinib
100 mg qd per day once a day. All patients were then
treated with consolidation therapy including Hyper
CVAD A scheme (cyclophosphamide, vincristine, dauno-
rubicin, and dexamethasone) and alternately Hyper
CVAD B scheme (high-dose methotrexate and cytara-
bine) following complete remission. Our study enrolled
96 cohorts undergoing their first or second remission
and who required allogenic hematopoietic stem cell
transplantation (Allo-HSCT). The procedure required
that all cohorts with diagnosed ALL should undergo
central nervous system (CNS) prophylaxis. Follow-up of
the ALL cohorts ran till August 1, 2015 (median follow-
up: 25.6 months, range: 1.2–78.9 months). Confirmed
complete molecular response (CMR) was defined as lower
than 0.0032 % [9].
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Statistical analysis
SPSS 17.0 software (SPSS Inc., Chicago, IL, USA) was
used to evaluate the statistical difference of categorical
variables between patient groups with the Pearson
Chi-square analysis and Fisher exact test. Disease-free
survival (DFS) was calculated from the date of complete
remission to the first relapse. The Kaplan–Meier method
and Log rank tests were performed to compare overall
survival (OS) between the groups, and a P value of less
than 0.05 was considered statistically significant.
Results
Characteristics of patients
One hundred thirty-five newly diagnosed Ph-positive
B-cell ALL patients (age 18–65, median 33.4) were en-
rolled. The characteristics of the patients are summarized
in Table 1. Of the 135 cases analyzed, 44 (32.6 %) patients
showed that they were carriers of CDKN2 deletion. No
significant differences were observed for age and gender
between CDKN2 deletion carriers and non-carriers. The
median white blood cell (WBC) count was 54.1 × 109/L
(range: 0.8~353.0). However, the initial WBC counts
and hepatosplenomegaly rate of CDKN2 deletion were
significantly higher than those of patients with no deletion
(P = 0.012, P = 0.006, respectively).
Immunophenotypic analysis
Of the 135 patients analyzed in our study, 127 received
immunophenotypic analysis, and the results are summa-
rized in Table 2. CD20 expression was defined as ≥20 %
cells that are positive with CD20. Within the subgroup
of CDKN2 deletion, 25 of 42 (59.5 %) patients analyzed
expressed CD20, and our results showed that there were
significant differences between the patients with and
without CDKN2 deletion in terms of CD20 expression
(P = 0.001).
Effect of CDKN2 deletion on complete molecular response
After the induction treatment, 124 patients achieved CR,
and no significant differences in CR rate were observed
between patients with or without CDKN2 deletion.
Eleven patients who failed to achieve CR died early due to
sepsis (n = 5), CNS (n = 2), or pulmonary failures (n = 3).
In the subgroup of CDKN2 deletion, 6 of 39 (15.4 %) pa-
tients analyzed achieved CMR after the induction treat-
ment, and the CMR rate was lower than the subgroup of
the wild-type CDKN2 gene (15.4 versus 32.9 %, P = 0.042).
After two to three courses of consolidation chemotherapy,
Table 1 Patient characteristics (N = 135)
Clinical characters CDKN2 deletion No CDKN2 deletion P value
Adults (sample size) 44 91
Male/female 24/20 53/38 0.684
Mean age (years) 33.3 (18–64) 35.4 (18–65) 0.368
WBC count (×109/L)a 107.7 (1.6~302.0) 69.8 (0.8~353.0) 0.012
Hepatosplenomegalya 26 (59.1 %) 31 (34.1 %) 0.006
Complete remission 39 (88.6 %) 85 (93.4 %) 0.337
Stem cell transplantation 34 (77.3 %) 62 (68.1 %) 0.272
Relapsea 26 (59.1 %) 32 (35.2 %) 0.008
WBC white blood cell
aComparison between CDKN2 deletion carriers and non-carriers
Fig. 1 Representative of fluorescence images in situ hybridization. a Normal cells presented with double green and red signals; b hemizygous
cells presented with loss of one red signal; c homozygous cells presented with a loss of both red signals (p16) and only retained with two green
signals (chromosome 9); d red and green signal fusion (BCR/ABL+)
Xu et al. Journal of Hematology & Oncology  (2016) 9:40 Page 3 of 8
34 patients with CDKN2 deletion and 62 patients with the
wild-type CDKN2 gene received allogeneic hematopoietic
stem cell transplantation (Allo-HSCT). The CMR rate
before Allo-HSCT was higher in the group with the wild-
type CDKN2 gene than in the group with CDKN2 de-
letion (77.4 versus 52.9 %, P = 0.013). Three cases out
of 34 patients with CDKN2 deletion and four cases
out of 62 patients without CDKN2 deletion did not
survive during the period of Allo-HSCT. After analyz-
ing the evaluable cases, the differences in CMR rates
were not observed after the Allo-HSCT (87 versus
93.1 %, P = 0.442) (Table 3).
The influence of CDKN2 deletion on different TKI treatments
Among 44 CDKN2 deletion patients, 26 cases received
imatinib treatment and 18 cases received dasatinib treat-
ment, and our results showed no difference in CR,
CMR, and relapse rates between patients who received
imatinib and those who received dasatinib treatment.
Also, no differences were observed in the OS and DFS
(Table 4).
Influence of CDKN2 deletion on DFS and OS
The median follow-up for 135 adults was 25.6 months
(1.2–78.9 months). The relapse rate in the CDKN2 dele-
tion subgroup was higher than in the subgroup with no
CDKN2 deletion (59.1 versus 35.2 %, P = 0.008) (Table 1).
OS and DFS curves are shown in Figs. 2 and 3. The
estimated 2-year overall survival and 2-year disease-free
survival rates by the Kaplan–Meier method for patients
with CDKN2 wild-type were 65.5 and 51.1 %, respectively,
and for patients with CDKN2 deletion were 35.2 and
23.3 %, respectively. The results revealed that CDKN2
deletion was associated with a significant inferior OS
(P = 0.004) and DFS (P = 0.005).
Influence of CD20 expression on BCR-ABL-positive B-ALL
with CDKN2 deletion
Forty-two patients out of 44 CDKN2 deletion patients
received immunophenotypic analysis. Analysis of the 42
cases showed that CDKN2 deletion patients with CD20
expression had an inferior OS and DFS than the patients
without CD20 expression. OS and DFS curves are shown
in Figs. 4 and 5. Our study showed no significant differ-
ence in relapse between the CD20-positive and CD20-
negative groups (P = 0.147).
Discussion
In the pre-TKI era, the prognosis of BCR-ABL-positive
B-ALL has been shown to be extremely unfavorable with
7 years of OS <50 % [10]. Recently, loss of tyrosine kinase
receptor in Ph-positive cells was found to result in
the development of ALL [11]. The development of TKIs
has also been reported to markedly improve the outcome
Table 2 Immunophenotype comparison between CDKN2 wild-
type and deletion





CD34 40 (95.2 %) 75 (88.2 %) 0.334
HLA-DR 42 (100 %) 81 (95.3 %) 0.301
CD45 20 (47.6 %) 28 (32.9 %) 0.109
TdT 2 (4.8 %) 2 (2.4 %) 0.599
CD117 2 (4.8 %) 1 (1.2 %) 0.254
CD10 40 (95.2 %) 79 (92.9 %) 1.000
CD19 41 (97.6 %) 82 (96.5 %) 1.000
CD20a 25 (59.5 %) 24 (28.2 %) 0.001
CD22 22 (52.4 %) 53 (62.4) 0.282
CD13 24 (57.1 %) 61 (71.8 %) 0.099
CD14 0 (0 %) 3 (3.5 %) 0.550
CD15 0 (0 %) 0 (0 %) N/A
CD33 24 (57.1 %) 34 (40 %) 0.068
CD2 3 (7.1 %) 5 (5.9 %) 1.000
CD3 1 (2.4 %) 0 (0 %) 0.331
CD7 0 (0 %) 4 (4.7 %) 0.301
CD56 4 (9.5 %) 4 (4.7 %) 0.438
CD64 2 (4.8 %) 5 (5.9 %) 1.000
CD11b 3 (7.1 %) 3 (3.5 %) 0.396
cCD79a 38 (90.5 %) 67 (78.8 %) 0.103
cMPO 0 (0 %) 0 (0 %) N/A
aComparison between CDKN2 deletion carriers and non-carriers









After inductiona 39/85 6 (15.4 %) 28 (32.9 %) 0.042
Pre-Allo-HSCTa 34/62 18 (52.9 %) 48 (77.4 %) 0.013
Post-Allo-HSCT 31/58 27 (87 %) 54 (93.1 %) 0.442
Allo-HSCT allogeneic hematopoietic stem cell transplantation
aComparison between CDKN2 deletion carriers and non-carriers
Table 4 Influence of CDKN2 deletion by different TKI
treatments
Imatinib (n = 26) Dasatinib (n = 18) P value
CR after induction 22/26 (84.6 %) 17/18 (94.4 %) 0.634
CMR after induction 2/23 (8.7 %) 4/16 (25.0 %) 0.205
Transplantation 19/26 (73.1 %) 15/18 (83.3 %) 0.489
Relapse 16/26 (61.5 %) 10/18 (55.6 %) 0.691
OS (median time) 16.5 (1.2–38.7) 18.4 (3–41.9) 0.508
DFS (median time) 12.9 (0–37.7) 14.2 (0–41) 0.555
CR complete remission, Allo-HSCT allogeneic hematopoietic stem cell
transplantation, DFS disease-free survival, OS overall survival
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of Ph-positive ALL [12–14]. However, there exists
enormous variation in response to chemotherapy with
the heterogeneity of biological and clinical outcomes
in leukemia patients [15–17]. CDKN2A/B deletion is
one of the most common genetic mutations involved
in leukemogenesis in Ph-positive ALL cells characterized
by recurrent genetic abnormalities along with BCR-ABL
fusions [18]. CDKN2A/B genes usually remain undetected
in hematopoietic stem cells and begin to activate following
blood cell differentiation process in response to potential
oncogenic stress [19–21]. The unchanged epigenetic in-
activation of CDKN2A/B(INK4-ARF) in differentiated
cells will result in an inappropriate self-renewal capacity
and leads to malignant transformation. Our current re-
sults reported the frequency of CDKN2 deletion as 32.6 %
(44/135) in adult Ph-positive B-ALL patients and agreed
with the previous observed incidence of CDKN2 deletion
in adult patients with the BCR-ABL fusion gene (29 %)
[5]. Our results showed that no difference occurred be-
tween CDKN2 deletion patients (44/135) and wild-type
patients with regard to sex, age, and induction complete
remission rate. CDKN2 deletion carriers demonstrated
greater white blood cell count, enhanced rates of hepatos-
plenomegaly, an upregulation of CD20 expression, and a
higher relapse rate. It is well known that accelerated
tumor cell proliferation could occur as a result of
CDKN2A/B deletion due to the direct removal of tumor
suppressors and activation of tumor growth factors such
as MDM2 and CDK4/6. This may explain why CDKN2
deletion patients present with higher WBC counts, and
hepatosplenomegaly is an indicator of a higher tumor
load. Currently, research regarding the effect of CD20 in
Fig. 2 Overall survival comparison among Ph-positive patients. Kaplan–Meier Curve demonstrated significantly a shorter survival time in CDKN2
wild-type patients than in CDKN2 deletion patients (P = 0.004)
Fig. 3 Disease-free survival comparison among Ph-positive patients. Kaplan–Meier Curve demonstrated a significantly shorter disease-free survival
time in CDKN2 wild-type patients than in CDKN2 deletion patients (P = 0.005). CR complete remission
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Ph-positive ALL patients has been controversial. Some re-
ports suggested that CD20 expression is not an adverse
factor [22, 23]. But, many studies found that expression of
CD20 is associated with an increased incidence of a re-
lapse [24], and CD20 upregulation is frequent in patients
who suffered later from a relapse [25]. Thus, CD20 ex-
pression had an adverse effect on the prognosis in patients
diagnosed with B-cell acute lymphoblastic leukemia
[26, 27]. For B-lymphoblastic leukemia patients who are
Ph-negative, the expression of CD20-positive patients has
shown some significant benefit from rituximab therapy,
especially towards younger aged patients [28, 29]. Ph-
positive ALL cohorts have been prescribed with a similar
type of therapy, and these patients most commonly
undergo monoclonal antibody therapy. Nevertheless, the
adverse expression of CD20 in this particular subtype of
ALL has yet to be determined and requires further exam-
ination [30]. In our study, the adult Ph-positive ALL pa-
tients with CDKN2 deletion had a higher rate of CD20
expression (at a level of at least 20 %), and these patients
with CD20 expression had an inferior OS and DFS than
the patients without CD20 expression. Hence, CD20
expression may be a cause of the inferior OS and DFS. To-
gether, CDKN2 deletion patients who exhibit a higher
CD20 expression could possibly benefit from rituximab
treatment. The efficacy of rituximab combination with
chemotherapy and its association with the improved sur-
vival of patients with ALL needs further research.
Fig. 4 Overall survival comparison among CDKN2 deletion patients received immunophenotypic analysis. Kaplan–Meier Curve demonstrated
significantly shorter survival time in CDKN2 deletion patients with CD20-positive patients than in CDKN2 deletion with CD20-negative
patients (P = 0.013)
Fig. 5 Disease-free survival comparison among CDKN2 deletion patients received immunophenotypic analysis. Kaplan–Meier Curve demonstrated a
significantly shorter disease-free survival time in CDKN2 deletion patients with CD20-positive patients than in CDKN2 deletion with CD20-negative
patients (P = 0.023). CR complete remission
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Results from the current study revealed that a shorter
survival time and a higher recurrence rate was observed
in Ph-positive ALL patients with CDKN2 deletion. Previ-
ous studies reported similar poor survival as a significant
clinical outcome and observed a short relapsed period
within 1 year in all of the adult BCP-ALL patients
concurrent with the BCR-ABL fusion gene and CDKN2
deletion [5, 31]. In previous studies, CDKN2 deletion was
not found in CML-CP patients, but had been detected in
part of CML-BC- and Ph-positive ALL patients [32, 33].
Commonly, the CDKN2 gene cluster was silenced in
CML-CP progenitors. However, during the process of
differentiation, the CDKN2 gene undergoes a series of
epigenetic changes in response to BCR-ABL-induced
oncogenic signals and consequently stimulates p53 which
degrades initial tumor cells via apoptosis. On the other
hand, the abnormal progenitors which sustain deletions
of the CDKN2 gene acquire an intrinsic self-renewing
ability and eventually contribute to the transition to CML
lymphoid blast crisis [34]. Previous studies in mouse
models, which injected mice with Arf−/− or Arf+/− p210
(BCR-ABL)-positive pre-B cells, demonstrated an aggres-
sive and a higher dose imatinib resistance model [35, 36].
Williams and his team suggested that the BCR-ABL fusion
gene and CDKN2 deletion interferes with the tumor sup-
pressor network of Rb and p53, thereby accelerating the
self-renewal of leukemia initial cells and enhancing its re-
sistance to the drug [37]. p16(INK4a) or p14(ARF) which
are transfected into primary blast cells from CML in
blast crisis (CML-BC) and Ph-positive ALL could result in
the inhibition of cell proliferation and an increase in cell
apoptosis and could further promote sensitivity to ima-
tinib [38]. Recent studies in Ph-positive ALL mouse
models showed the attenuation effect of silenced CDKN2
to targeted BCR-ABL kinase inhibitors. Also, CDKN2 in-
activation contributes to the prolonged survival of
leukemia-initiating cells within the hematopoietic stem
cell (HSC) environment and gives rise to the formation of
malignant clone cells containing drug-resistant BCR-ABL
kinase mutations [35, 36]. Typically, BCR-ABL mutations
represent drug resistance in Ph-positive ALL patients, but
the deletion of CDKN2 in Ph-positive ALL patients fur-
ther exacerbates the disease condition and eliminates the
favorable outcome of targeted therapy. Together, these
mechanisms may explain why additional imatinib or dasa-
tinib therapy presents a poor prognosis in Ph-positive
ALL patients with CDKN2 deletion.
Conclusions
In conclusion, our study assessed Ph-positive ALL pa-
tients who presented with CDKN2 deletion and showed
that they have a higher rate of CD20 expression. CDKN2
deletion and CD20 expression act as unfavorable prognostic
markers for Ph-positive ALL patients despite undergoing
tyrosine kinase inhibitor-based therapies. These results
provide a better understanding regarding the import-
ance of genetic events, and the study emphasizes a need
to pay attention to the Ph-positive B-ALL patients with
CDKN2 deletion who could potentially benefit from
anti-CD20-directed immunotherapy.
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